hVIVO (OPORF) Beginning Cash Position: $31.18 Mil (As of Dec. 2025)


OPORF hVIVO PLC OPORF
48 GF Score
Price $0.11
GF Value $0.60
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is hVIVO Beginning Cash Position?

hVIVO OPORF +27.29% 48 Beginning Cash Position is $31.18 Mil as of Dec. 2025. GuruFocus rates OPORF with a GF Score™ of 48/100 and a GF Value™ of $0.60 (Possible Value Trap). The stock has 6 warning signs investors should review.

hVIVO's Beginning Cash Position for the quarter that ended in Dec. 2025 was $31.18 Mil.

hVIVO's quarterly Beginning Cash Position increased from Dec. 2024 ($46.90 Mil) to Jun. 2025 ($59.95 Mil) but then declined from Jun. 2025 ($59.95 Mil) to Dec. 2025 ($31.18 Mil).

hVIVO's annual Beginning Cash Position increased from Dec. 2023 ($36.00 Mil) to Dec. 2024 ($46.74 Mil) and increased from Dec. 2024 ($46.74 Mil) to Dec. 2025 ($59.14 Mil).

hVIVO Beginning Cash Position Related Terms

hVIVO Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for hVIVO's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

hVIVO Beginning Cash Position Chart

hVIVO Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.54 19.12 36.00 46.74 59.14

hVIVO Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.68 47.04 46.90 59.95 31.18
OPORF
48GF Score
hVIVO PLC OPORF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

hVIVO Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $31.18 Mil mean?
hVIVO (OPORF) has a Beginning Cash Position of $31.18 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on hVIVO and its competitors.
Is hVIVO's Beginning Cash Position too high?
hVIVO's current Beginning Cash Position is $31.18 Mil. Overall, hVIVO has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does hVIVO's Beginning Cash Position compare to TMO and DHR?
hVIVO's Beginning Cash Position of $31.18 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Diagnostics & Research company?
A good Beginning Cash Position depends on the Medical Diagnostics & Research industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on hVIVO and its competitors. hVIVO's current Beginning Cash Position is $31.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is hVIVO stock overvalued right now?
Based on GuruFocus' analysis, hVIVO (OPORF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.11 — trading 81.7% below its estimated fair value. The current Beginning Cash Position is $31.18 Mil. hVIVO's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For hVIVO (OPORF), the current Beginning Cash Position is $31.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is hVIVO (OPORF) Overvalued in 2026?

Based on GuruFocus' analysis, hVIVO stock appears to be undervalued. The current stock price of $0.11 is trading 81.7% below its estimated GF Value™ of $0.60. GuruFocus considers hVIVO to be Possible Value Trap.

Key valuation signals for OPORF:

  • Beginning Cash Position: $31.18 Mil
  • GF Value™: $0.60 vs. price of $0.11 (81.7% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

hVIVO Business Description

Other Exchanges HVO:UKCRO:Germany
Address 40 Bank Street, Floor 24, London, GBR, E14 5NR
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
48GF Score

Get the complete analysis for OPORF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.60
GF Value